fbpx

Pioneering Off‑the‑Shelf, Allogeneic T‑Cell Immunotherapies

Mission to transform the lives of patients with serious medical conditions through pioneering science, teamwork and a commitment to excellence

About Us

Robust T‑Cell Immunotherapy Pipeline

Four Strategic Priorities

  • Tab-cel® (tabelecleucel)
  • ATA188
  • ATA2271 & ATA3271
  • ATA3219
View Pipeline

Patient Stories

“I learned how to cultivate wonder about life’s simple moments because I didn’t know how many moments I had left.”
Doug
“Don’t give up. That’s the main thing.”
Ayden
“I have always been very aware of the preciousness of life and that it is something we cannot take for granted.”
Jessica
“I am who I am because of my disability. People read my story and say, ‘You are a role model to me.’ Hearing that from others is what drives me forward.”
Ola
Doug Ayden Jessica Ola
View Patient Stories
Doug

Patient Stories

“I learned how to cultivate wonder about life’s simple moments because I didn’t know how many moments I had left.”
Doug
Ayden

Patient Stories

“Don’t give up. That’s the main thing.”
Ayden
Jessica

Patient Stories

“I have always been very aware of the preciousness of life and that it is something we cannot take for granted.”
Jessica
Ola

Patient Stories

“I am who I am because of my disability. People read my story and say, ‘You are a role model to me.’ Hearing that from others is what drives me forward.”
Ola
View Patient Stories
World-Class T‑Cell Manufacturing

World-Class T‑Cell Manufacturing

Flexibility to produce multiple T‑cell and CAR T immunotherapies

Dedicated, expandable ATOM (Atara T‑Cell Operations & Manufacturing) facility in Thousand Oaks, CA

View Manufacturing

Latest News

May 27, 2020

Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering

View Press Release View All Press Releases View Press Release
May 26, 2020

Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre‑Funded Warrants

View Press Release View All Press Releases View Press Release
May 26, 2020

Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late‑Breaking e‑Poster at the 2020 European Academy of Neurology Virtual Congress

View Press Release View All Press Releases View Press Release

Follow Atara Biotherapeutics on LinkedIn to stay up-to-date on the latest developments and pursuit of our mission to transform the lives of patients with serious medical conditions through pioneering science, teamwork and a commitment to excellence.
Linkedin

Follow Us